ClinicalTrials.gg
CompletedNCT02274558KINECT 3Updated Jul 11, 2017Results posted

A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia

A Phase 3 interventional study of NBI-98854 and Placebo in Tardive Dyskinesia, sponsored by Neurocrine Biosciences. Completed at 54 sites in 3 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2017-07-11.

Sponsored by Neurocrine Biosciences · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
234
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing valbenazine in Tardive Dyskinesia — 1 open to participants now, 1 under way, none of them phase 3. valbenazine · Tardive Dyskinesia.

Enrollment
2nd of 14
234 · median 101
Started
2014
the only one that year
Phase 3
3 of 14
none open now
Registered
5th of 14
by date
Lead sponsor
11 of 14
Neurocrine Biosciences

Among the 14 studies testing valbenazine in Tardive Dyskinesia, this one is the 2nd largest by enrollment, is the only one that started in 2014, is one of 3 in phase 3, and was the 5th registered.

Tardive Dyskinesia

62 studies on the registry are indexed under Tardive Dyskinesia; 9 are open to participants now.

Browse Tardive Dyskinesia studies →

Open to participants now

1 of the 14 studies testing valbenazine in Tardive Dyskinesia is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Where they have run

About valbenazine

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 7 Tardive Dyskinesia studies recruiting now, 2 set no upper age limit and 4 stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing valbenazine in Tardive Dyskinesia, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy, safety, and tolerability of NBI-98854 administered once daily for the treatment of Tardive Dyskinesia (TD) symptoms.

Read the detailed description

This is a Phase 3, randomized, double-blind, placebo-controlled, parallel, fixed-dose study to evaluate the efficacy, safety, and tolerability of two doses of NBI-98854 (40 mg and 80 mg) compared to placebo, administered once daily. The study design includes a double-blind, placebo-controlled treatment period for 6 weeks and a double-blind NBI-98854 treatment period for an additional 42 weeks, for a total of 48 weeks of treatment. Final follow-up assessments will be conducted 4 weeks after the last dose of the study drug.

03

Conditions studied

  • Tardive Dyskinesia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects of must agree to use hormonal or two forms of nonhormonal (dual contraception) consistently during the screening, treatment and follow-up periods of the study.
  2. Female subjects must not be pregnant.
  3. Have one of the following clinical diagnoses for at least 3 months prior to screening: Schizophrenia or Schizoaffective Disorder, or Mood Disorder.
  4. Have a clinical diagnosis of neuroleptic-induced TD for at least 3 months prior to screening.
  5. Have moderate or severe TD.
  6. If using maintenance medication(s) for schizophrenia or schizoaffective disorder, or mood disorder, be on stable doses.
  7. Be in good general health.
  8. Have adequate hearing, vision, and language skills to perform the procedures specified in the protocol.
  9. Have a negative drug screen for amphetamines,barbiturates, benzodiazepines, phencyclidine, cocaine, opiates, or cannabinoids

Exclusion criteria

Exclusion Criteria:

  1. Have an active, unstable medical condition within 1 month prior to screening.
  2. Have a known history of substance dependence, or substance (drug) or alcohol abuse
  3. Have a significant risk of suicidal or violent behavior.
  4. Have a known history of neuroleptic malignant syndrome.
  5. Have a known history of long syndrome or cardiac tachy-arrhythmia.
  6. Have a cancer diagnosis within 3 years of screening (some exceptions allowed)
  7. Have received an drug within 30 days prior to screening or plan to use an investigational drug (other than NBI-98854) during the study.
  8. Have a blood loss ≥550 mL or donated blood within 30 days prior to Baseline.
  9. Have an allergy, , or intolerance to tetrabenazine.
  10. Have had previous exposure with NBI-98854 or had previously participated in an NBI-98854 clinical study.
  11. Are currently pregnant or breastfeeding.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
234 participants (actual)

Study arms

  • Experimental
    NBI-98854 40 mg

    NBI-98854 administered as one (1) 40 mg capsule and one (1) placebo capsule, taken by mouth, every morning between 7:00am - 10:00am for 6 weeks. At the end of Week 6, subjects will enter a double-blind NBI-98854 treatment period and continue with their current dose.

    Drug: NBI-98854 · Drug: Placebo

  • Experimental
    NBI-98854 80 mg

    Subjects randomized to the NBI-98854 80 mg dose will receive NBI-98854 40 mg for the first week (administered as one (1) 40 mg capsule and one (1) placebo capsule), followed by NBI-98854 80 mg administered as two (2) 40 mg capsules, taken by mouth, every morning between 7:00am - 10:00am for 5 weeks. At the end of Week 6, subjects will enter a double-blind NBI-98854 treatment period and continue with their current dose.

    Drug: NBI-98854 · Drug: Placebo

  • Experimental
    Placebo

    Placebo administered as two (2) placebo capsules, taken by mouth, every morning between 7:00am - 10:00am for 6 weeks. At the end of Week 6, subjects will enter a double-blind NBI-98854 treatment period and be randomized to either a 40 mg or 80 mg dose. Subjects re-randomized to receive NBI-98854 80 mg will receive 40 mg for the first week.

    Drug: NBI-98854 · Drug: Placebo

Interventions

  • NBI-98854 40 mg capsules

  • DrugPlacebo

    NBI-98854 placebo capsules

06

What researchers measure

Primary outcomes

  1. Abnormal Involuntary Movement Scale (AIMS) Dyskinesia Total Score Change From Baseline at Week 6

    Severity of TD symptoms assessed by AIMS dyskinesia total score (sum of items 1 through 7), as assessed by blinded central AIMS video raters. The AIMS Total Dyskinesia Score rates a total of 7 items, rating involuntary movement from 0 (no dyskinesia) to 4 (severe dyskinesia). Items 1 through 7 include facial and oral movements (Items 1-4), extremity movements (Items 5-6), and trunk movements (Item 7). The AIMS dyskinesia total score for Items 1-7 ranges from 0 to 28; a higher score reflects increased severity.

    Time frame: Baseline and Week 6

Secondary outcomes

  1. Clinical Global Impression of Change - TD (CGI-TD) at Week 6

    Clinician's perspective of the participant's overall improvement of TD symptoms over time. The CGI-TD is based on a 7-point scale (range: 1=very much improved to 7=very much worse).

    Time frame: Week 6

  2. Abnormal Involuntary Movement Scale (AIMS) Dyskinesia Total Score Responder Analysis at Week 6

    Percentage of AIMS responders (subjects who had at least a 50 percent reduction in AIMS score from baseline)

    Time frame: Week 6

07

Results

Posted Jul 11, 2017

Participant flow

This study enrolled patients with schizophrenia or schizoaffective disorder with tardive dyskinesia (TD) or mood disorder with TD from 63 centers in North America and Puerto Rico. The last patient completed in August 2016.

Participant flow — Overall Study
MilestonePlacebo-Controlled PlaceboPlacebo-Controlled Valbenazine 40mgPlacebo-Controlled Valbenazine 80mg
Started787680
Included in the safety analysis set767279
Completed716371
Not completed7139
Withdrew: Adverse event242
Withdrew: Non-compliance210
Withdrew: Withdrawal by subject154
Withdrew: Death001
Withdrew: Lost to follow-up211
Withdrew: Physician decision021

Outcome measures

PrimaryAbnormal Involuntary Movement Scale (AIMS) Dyskinesia Total Score Change From Baseline at Week 6

Severity of TD symptoms assessed by AIMS dyskinesia total score (sum of items 1 through 7), as assessed by blinded central AIMS video raters. The AIMS Total Dyskinesia Score rates a total of 7 items, rating involuntary movement from 0 (no dyskinesia) to 4 (severe dyskinesia). Items 1 through 7 include facial and oral movements (Items 1-4), extremity movements (Items 5-6), and trunk movements (Item 7). The AIMS dyskinesia total score for Items 1-7 ranges from 0 to 28; a higher score reflects increased severity.

Time frame:
Baseline and Week 6
Reported as:
Least squares mean · scores on a scale
Abnormal Involuntary Movement Scale (AIMS) Dyskinesia Total Score Change From Baseline at Week 6
scores on a scalePlaceboValbenazine 80mgValbenazine 40mg
Abnormal Involuntary Movement Scale (AIMS) Dyskinesia Total Score Change From Baseline at Week 6-0.1 ± 0.4-3.2 ± 0.4-1.9 ± 0.4
Statistical analysis
  • Placebo vs Valbenazine 80mg · Mixed-effect Model Repeated Measures · p = <0.0001 · Mean difference (final values): -3.1 · 95% CI -4.2 to -2.0
  • Placebo vs Valbenazine 40mg · Mixed-effect Model Repeated Measures · p = 0.0021 (Nominal P-value, not adjusted for multiplicity. See comments in above statistical analysis overview regarding the fixed-sequence testing procedure to control for multiplicity.) · Mean difference (final values): -1.8 · 95% CI -3.0 to -0.7
SecondaryClinical Global Impression of Change - TD (CGI-TD) at Week 6

Clinician's perspective of the participant's overall improvement of TD symptoms over time. The CGI-TD is based on a 7-point scale (range: 1=very much improved to 7=very much worse).

Time frame:
Week 6
Reported as:
Least squares mean · scores on a scale
Clinical Global Impression of Change - TD (CGI-TD) at Week 6
scores on a scalePlaceboValbenazine 40mgValbenazine 80mg
Clinical Global Impression of Change - TD (CGI-TD) at Week 63.2 ± 0.12.9 ± 0.12.9 ± 0.1
Statistical analysis
  • Placebo vs Valbenazine 40mg · Mixed-effect Model Repeated Measures · p = 0.0742 · Mean difference (final values): -0.3 · 95% CI -0.5 to 0.0
  • Placebo vs Valbenazine 80mg · Mixed-effect Model Repeated Measures · p = 0.0560 · Mean difference (final values): -0.3 · 95% CI -0.5 to 0.0
SecondaryAbnormal Involuntary Movement Scale (AIMS) Dyskinesia Total Score Responder Analysis at Week 6

Percentage of AIMS responders (subjects who had at least a 50 percent reduction in AIMS score from baseline)

Time frame:
Week 6
Reported as:
Count of participants · Participants
Abnormal Involuntary Movement Scale (AIMS) Dyskinesia Total Score Responder Analysis at Week 6
ParticipantsPlaceboValbenazine 40mgValbenazine 80mg
Abnormal Involuntary Movement Scale (AIMS) Dyskinesia Total Score Responder Analysis at Week 661528
Statistical analysis
  • Placebo vs Valbenazine 40mg · Cochran-Mantel-Haenszel · p = 0.0200
  • Placebo vs Valbenazine 80mg · Cochran-Mantel-Haenszel · p = <0.0001

Adverse events

Collected over up to 6 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/76 (0%)3/76 (3.9%)7/76 (9.2%)
Valbenazine 40mg0/72 (0%)4/72 (5.6%)9/72 (12.5%)
Valbenazine 80mg1/79 (1.3%)6/79 (7.6%)5/79 (6.3%)
Most frequent serious events
Showing 10 of 13
Most frequent serious events
EventPlaceboValbenazine 40mgValbenazine 80mg
Gastroenteritis viralInfections and infestations0/761/720/79
Pyelonephritis acuteInfections and infestations0/761/720/79
Bipolar I disorderPsychiatric disorders0/761/720/79
HostilityPsychiatric disorders0/761/720/79
Mental status changesPsychiatric disorders1/761/720/79
SchizophreniaPsychiatric disorders1/761/720/79
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders0/761/720/79
Schizoaffective disorderPsychiatric disorders1/760/721/79
Sudden DeathGeneral disorders0/760/721/79
Hepatitis acuteHepatobiliary disorders0/760/721/79
Most frequent other events
Most frequent other events
EventPlaceboValbenazine 40mgValbenazine 80mg
Dry mouthGastrointestinal disorders1/765/720/79
SomnolenceNervous system disorders3/764/724/79
Suicidal ideationPsychiatric disorders4/763/721/79

Baseline characteristics

Safety analysis set: Included all subjects who were randomized to a treatment group and dispensed study drug, with the following 2 exclusions: (a) subjects who withdrew from the study and returned all previously dispensed study drug with all doses present, and (b) subjects who had no postbaseline safety data collected.

Age, Continuous
Age, Continuous(years)Placebo-Controlled PlaceboPlacebo-Controlled Valbenazine 40mgPlacebo-Controlled Valbenazine 80mgTotal
Mean57.0 (30 to 84)55.3 (26 to 74)56.0 (32 to 83)56.1 (26 to 84)
Sex: Female, Male
Sex: Female, Male(Participants)Placebo-Controlled PlaceboPlacebo-Controlled Valbenazine 40mgPlacebo-Controlled Valbenazine 80mgTotal
Female343040104
Male424239123
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Placebo-Controlled PlaceboPlacebo-Controlled Valbenazine 40mgPlacebo-Controlled Valbenazine 80mgTotal
American Indian or Alaska Native0112
American Indian or Alaska Native, Caucasian0112
Asian0101
Black or African American29263287
Caucasian434144128
Native Hawaiian or Other Pacific Islander1001
Other: Arabic1001
Other: Hispanic0011
Other: Mexican1102
Other: Mixed1102
Body Mass Index
Body Mass Index(kg/m^2)Placebo-Controlled PlaceboPlacebo-Controlled Valbenazine 40mgPlacebo-Controlled Valbenazine 80mgTotal
Mean28.03 (18.1 to 42.2)28.64 (19.4 to 40.6)27.78 (18.2 to 46.9)28.13 (18.1 to 46.9)
Psychiatric Diagnosis Category
Psychiatric Diagnosis Category(Participants)Placebo-Controlled PlaceboPlacebo-Controlled Valbenazine 40mgPlacebo-Controlled Valbenazine 80mgTotal
Schizophrenia/Schizoaffective disorder504852150
Mood disorder26242777
Age at TD Diagnosis
Age at TD Diagnosis(years)Placebo-Controlled PlaceboPlacebo-Controlled Valbenazine 40mgPlacebo-Controlled Valbenazine 80mgTotal
Mean49.4 (29 to 81)47.8 (22 to 67)47.6 (17 to 72)48.2 (17 to 81)
BPRS Total Score
BPRS Total Score(units on a scale)Placebo-Controlled PlaceboPlacebo-Controlled Valbenazine 40mgPlacebo-Controlled Valbenazine 80mgTotal
Mean29.3 (18 to 46)30.6 (20 to 48)29.1 (18 to 48)29.7 (18 to 48)
Baseline AIMS Total Dyskinesia Score
Baseline AIMS Total Dyskinesia Score(units on a scale)Placebo-Controlled PlaceboPlacebo-Controlled Valbenazine 40mgPlacebo-Controlled Valbenazine 80mgTotal
Mean9.9 ± 4.39.7 ± 4.110.4 ± 3.610.0 ± 4.0
08

Study locations

54 sites
  • Little Rock, Arkansas, United States
  • Anaheim, California, United States
  • Glendale, California, United States
  • Irvine, California, United States
  • Long Beach, California, United States
  • Los Angeles, California, United States
  • National City, California, United States
  • Norwalk, California, United States
  • Oakland, California, United States
  • Oceanside, California, United States
  • San Bernardino, California, United States
  • San Diego, California, United States
  • Torrance, California, United States
  • Bradenton, Florida, United States
  • Hialeah, Florida, United States
  • Kissimmee, Florida, United States
  • Leesburg, Florida, United States
  • Maitland, Florida, United States
  • Miami, Florida, United States
  • North Miami, Florida, United States
  • Chicago, Illinois, United States
  • Oak Brook, Illinois, United States
  • Shreveport, Louisiana, United States
  • Baltimore, Maryland, United States
  • Glen Burnie, Maryland, United States
  • Worcester, Massachusetts, United States
  • Flowood, Mississippi, United States
  • Saint Louis, Missouri, United States
  • Lincoln, Nebraska, United States
  • Amherst, New York, United States
  • Cedarhurst, New York, United States
  • Rochester, New York, United States
  • Durham, North Carolina, United States
  • Pinehurst, North Carolina, United States
  • Dayton, Ohio, United States
  • Shaker Heights, Ohio, United States
  • Oklahoma City, Oklahoma, United States
  • Conshohocken, Pennsylvania, United States
  • Norristown, Pennsylvania, United States
  • Phoenixville, Pennsylvania, United States
  • Scranton, Pennsylvania, United States
  • Charleston, South Carolina, United States
  • Memphis, Tennessee, United States
  • DeSoto, Texas, United States
  • Fort Worth, Texas, United States
  • Irving, Texas, United States
  • Petersburg, Virginia, United States
  • Spokane, Washington, United States
  • Vancouver, British Columbia, Canada
  • London, Ontario, Canada
  • Toronto, Ontario, Canada
  • Montreal, Quebec, Canada
  • Caguas, Puerto Rico
  • San Juan, Puerto Rico
09

References and documents

Publications

  • Sajatovic M, Alexopoulos GS, Burke J, Farahmand K, Siegert S. The effects of valbenazine on tardive dyskinesia in older and younger patients. Int J Geriatr Psychiatry. 2020 Jan;35(1):69-79. doi: 10.1002/gps.5218. Epub 2019 Oct 31. PubMed 31617235 ↗
  • Correll CU, Cutler AJ, Kane JM, McEvoy JP, Liang GS, O'Brien CF. Characterizing Treatment Effects of Valbenazine for Tardive Dyskinesia: Additional Results From the KINECT 3 Study. J Clin Psychiatry. 2018 Dec 18;80(1):18m12278. doi: 10.4088/JCP.18m12278. PubMed 30695293 ↗
  • Factor SA, Remington G, Comella CL, Correll CU, Burke J, Jimenez R, Liang GS, O'Brien CF. The Effects of Valbenazine in Participants with Tardive Dyskinesia: Results of the 1-Year KINECT 3 Extension Study. J Clin Psychiatry. 2017 Nov/Dec;78(9):1344-1350. doi: 10.4088/JCP.17m11777. PubMed 29141124 ↗
  • Kane JM, Correll CU, Liang GS, Burke J, O'Brien CF. Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Schizophrenia or Schizoaffective Disorder. Psychopharmacol Bull. 2017 Aug 1;47(3):69-76. PubMed 28839342 ↗
  • Josiassen RC, Kane JM, Liang GS, Burke J, O'Brien CF. Long-Term Safety and Tolerability of Valbenazine (NBI-98854) in Subjects with Tardive Dyskinesia and a Diagnosis of Schizophrenia or Mood Disorder. Psychopharmacol Bull. 2017 Aug 1;47(3):61-68. PubMed 28839341 ↗
  • Grigoriadis DE, Smith E, Hoare SRJ, Madan A, Bozigian H. Pharmacologic Characterization of Valbenazine (NBI-98854) and Its Metabolites. J Pharmacol Exp Ther. 2017 Jun;361(3):454-461. doi: 10.1124/jpet.116.239160. Epub 2017 Apr 12. PubMed 28404690 ↗
  • Hauser RA, Factor SA, Marder SR, Knesevich MA, Ramirez PM, Jimenez R, Burke J, Liang GS, O'Brien CF. KINECT 3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Valbenazine for Tardive Dyskinesia. Am J Psychiatry. 2017 May 1;174(5):476-484. doi: 10.1176/appi.ajp.2017.16091037. Epub 2017 Mar 21. PubMed 28320223 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2014, a primary completion of Sep 2015 and a completion of Jul 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2017, 1 year 10 months after primary completion. A results delay was requested in Oct 2016.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 22, 2014
First posted
Oct 24, 2014
Start
Oct 2014
Primary completionActual
Sep 2015
CompletionActual
Jul 2016
Results delay requested
Oct 12, 2016
Results first posted
Jul 11, 2017
Last update
Jul 11, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 11, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02274558
Responsible party
Sponsor
First posted
Oct 24, 2014
Start date
Oct 2014
Primary completion
Sep 2015
Completion
Jul 2016
Results posted
Jul 11, 2017
Last update
Jul 11, 2017

Study contacts

Chris O'Brien, MD
principal investigator · Neurocrine Biosciences

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Valbenazine

Start the discussion